BURLINGTON, ON, Dec. 11, 2012 /PRNewswire/ - EKO INTERNATIONAL CORP. - (EKNL - Pinksheets) is pleased to announce that NeuroVasc Clinical Inc. (NCI) has made arrangements to attend the Walmart Canada Professional Services Conferences of 2013 in Vancouver, BC ( April 4-7) and in Toronto, ON ( April 25-28). The Conference will provide NCI with access to 350 Walmart Pharmacists across Canada. NCI will present information explaining the benefits available to patients suffering with Diabetic Peripheral Neuropathy (DPN) by receiving FREMS treatments. FREMS will be showcased at the conference and the procedures for administering the treatment of patients diagnosed with DPN will be demonstrated to Walmart's Healthcare Providers. NCI will present its state-of-the-art equipment as part of the solution to Walmart's search for leading edge professional strategies and tools to promote sustainable practice changes in the delivery of health care. Diabetes Educators at Walmart Pharmacies throughout Ontario are currently able to provide accurate testing for (DPN) and it is the goal of NCI to have this capability expanded to all Walmart Pharmacies across Canada. Pharmacists provide the front line of care and support to most diabetic patients in Canada. At these two important conferences, NCI will ensure that the role of accurate testing for peripheral neuropathy is reinforced and demonstrated. Further, NCI can provide support to those patients identified as suffering from peripheral neuropathy by informing their pharmacist and/or diabetic educator of a FREMs facility within the community to which they can directly refer those patients. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by EKO International ("The Company") are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.